AEON Biopharma (AEON) Projected to Post Quarterly Earnings on Wednesday

AEON Biopharma (NASDAQ:AEON) is anticipated to release its results before the market opens on Wednesday, April 1st. Analysts expect AEON Biopharma to post earnings of ($0.17) per share for the quarter.

AEON Biopharma Price Performance

AEON opened at $1.06 on Wednesday. AEON Biopharma has a 12 month low of $0.38 and a 12 month high of $1.45. The business has a 50-day moving average of $1.12 and a two-hundred day moving average of $0.99. The stock has a market capitalization of $12.55 million, a price-to-earnings ratio of 5.89 and a beta of 0.72.

Hedge Funds Weigh In On AEON Biopharma

A hedge fund recently raised its stake in AEON Biopharma stock. Geode Capital Management LLC raised its position in AEON Biopharma, Inc. (NASDAQ:AEON) by 27.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 60,134 shares of the company’s stock after purchasing an additional 13,061 shares during the quarter. Geode Capital Management LLC owned 0.51% of AEON Biopharma worth $66,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 22.78% of the company’s stock.

AEON Biopharma Company Profile

AEON Biopharma, Inc, formerly Allied Energy Corp., is a clinical‐stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. The company applies enzyme replacement and gene therapy platforms to address unmet medical needs in central nervous system and metabolic disorders. Its lead program, AES-103, is being developed as an enzyme replacement therapy for Crigler-Najjar syndrome, a hereditary condition characterized by high levels of unconjugated bilirubin.

Beyond AES-103, AEON Biopharma is advancing AES-201 for X-linked adrenoleukodystrophy (X-ALD), a progressive neurological disorder, and AES-104 for post–COVID-19 conditions, commonly referred to as “long COVID.” These programs are in preclinical or early clinical stages, with ongoing efforts to optimize delivery, evaluate safety profiles and establish proof of concept.